Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Scheipl, S; Froehlich, EV; Leithner, A; Beham, A; Quehenberger, F; Mokry, M; Stammberger, H; Varga, PP; Lazary, A; Windhager, R; Gattenloehner, S; Liegl, B.
Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study.
Histopathology. 2012; 60(6):999-1003
Doi: 10.1111/j.1365-2559.2012.04186.x
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Fröhlich-Sorger Elke Verena
- Liegl-Atzwanger Bernadette
- Scheipl Susanne
- Co-Autor*innen der Med Uni Graz
- Beham Alfred
- Gattenlöhner Stefan
- Leithner Andreas
- Mokry Michael
- Quehenberger Franz
- Stammberger Heinz
- Windhager Reinhard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Scheipl S, Froehlich E V, Leithner A, Beham A, Quehenberger F, Mokry M, Stammberger H, Varga P P, Lazary A, Windhager R, Gattenloehner S & Liegl B (2012) Histopathology 60, 999-1003 Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study Aims: The overall prognosis of chordoma is poor, and current treatment options are limited. The insulin-like growth factor 1 receptor (IGF-1R) pathway is important for cell signalling, and attractive for selective inhibition. We investigated the expression of IGF-1R and its ligands, IGF-1 and IGF-2, in a series of 50 chordomas, in order to assess whether IGF-1R-signalling could be a potential target for specific inhibition in chordomas. Methods and results: Fifty chordomas (34 primary tumours, 16 recurrences) from 44 patients were evaluated immunohistochemically for the expression of IGF-1R, IGF-1 and IGF-2. Thirty-eight chordomas (76%) expressed IGF-1R, 46 (92%) expressed IGF-1 and 25 (50%) expressed IGF-2. Semi-quantitative analyses revealed a moderate to strong staining intensity in =50% of tumour cells for IGF-1R, IGF-1 and IGF-2 in 18 (36%), 32 (64%) and eight (16%) chordomas, respectively. Tumour volume correlated significantly with IGF-1R-staining intensity in primary chordomas (P = 0.042). Conclusions: IGF-1R and IGF-1 are expressed in the majority of chordomas. IGF-1 expression is much stronger than IGF-2 expression. Patients whose chordomas show a moderate to strong staining intensity in =50% of tumour cells for IGF-1R (36%) might benefit most from IGF-1R targeting, particularly if they suffer from large and surgically non-resectable chordomas.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Age Factors -
- Aged -
- Aged, 80 and over -
- Chordoma - diagnosis Chordoma - metabolism Chordoma - mortality
- Female -
- Female - epidemiology
- Humans -
- Insulin-Like Growth Factor I - metabolism
- Insulin-Like Growth Factor II - metabolism
- Male -
- Middle Aged -
- Molecular Targeted Therapy -
- Neoplasm Recurrence, Local -
- Prognosis -
- Receptor, IGF Type 1 - metabolism
- Retrospective Studies -
- Spinal Neoplasms - diagnosis Spinal Neoplasms - metabolism Spinal Neoplasms - mortality
- Survival Rate -
- Tumor Markers, Biological - metabolism
- Young Adult -
- Find related publications in this database (Keywords)
- brachyury
- chordoma
- IGF-1
- IGF-1R
- IGF-1-signalling
- IGF-2
- immunohistochemistry
- survival
- targeted therapies